If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock that could deliver huge gains in a defined time frame.Citing positive developments in its development programs, analysts from a couple of investment banks think CRISPR Therapeutics (CRSP -2.12%) could more than double your money in the year ahead.But before committing any amount of your own money to this stock, it's important to remember the analysts who recommended it have very little t ...

-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic prior ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run.To be clear, it doesn't always work out that way, and there are risks with these types of stoc ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of ...

Background and Expertise - The analyst has a strong background in life sciences with a PhD in Bioengineering and over 20 years of experience in the research and development of novel Cell & Gene Therapies (CGT) [2] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [2] Disclosure and Independence - The analyst has no stock, option, or similar derivative positions in any of the companies mentioned and no plans to initiate any such positions within the next 72 hours [1] - The analyst is not receiving compensation for the article other than from Seeking Alpha and has no business relationship with any company whose stock is mentioned [1] - The analyst is associated with another Seeking Alpha contributor, "Euro Invest," but each works independently and adheres to Seeking Alpha's Shared Association Guidelines [2]

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies in synthetic biology, engineer biological systems for practical applications, including pharmaceuticals and agriculture, using genetic engineering and biotechnology techniques to design novel organisms and processes. The promise of curing genetic diseases and extending human lifespan position ...

What's going on with CRISPR Therapeutics (CRSP 0.83%)? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date.Can CRISPR Therapeutics bounce back? Some recent developments could move the needle for the gene-editing specialist down the road. Let's find out what they are and what they mean for investors.Expanded coverage for CRISPR Therapeutics' crown jewelSince November 2 ...

CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth. Plus, investors just got another big green flag to invest in its stock.Here's what you need to know.This new development augurs a bright futurePer the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the Food and Drug Administr ...

Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing dea ...

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (CRSP 1.05%) first treatment last December, and its successful launch could push the stock much higher.  Investment bank analysts also expect Iovance Biotherapeutics (IOVA 0.13%) to soar in 2025.Before chasing exciting price targets, thou ...